Oslo, Norway, 14 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the resolution by the Company's extraordinary general meeting to carry out a reverse share split of the Company's shares. Key information related to the reverse share split, including the relevant key dates that have been determined by the board of directors today in accordance with the resolution by the general meeting, is set out below:

• Date on which the corporate action was made public: 18 December 2025
• Reverse split ratio: 100:1, i.e. one hundred (100) old shares give one (1) new share
• Last day including right: 16 January 2026
• Ex-date: 19 January 2026
• Record date: 20 January 2026
• Date of approval: 8 January 2026

Following completion of the reverse share split, the par value of the Company's shares will be increased from NOK 0.50 to NOK 50. Shareholders who do not own a number of shares which can be divided by 100 shall, in connection with the reverse share split, have their holdings rounded downwards, so that the shareholder receives a whole number of shares. Fractional shares will not be issued and the shareholders will not receive any compensation for the rounding. The fractional shares will be added together to whole shares and will be sold at the Oslo Stock Exchange. The net proceeds from the sale shall be donated to charity as determined by the board of directors.

In connection with the reverse share split, the Company's shares will be transferred to a new ISIN.

Please note the following key information for the change of ISIN:

• Issuer: Oncoinvent ASA
• Previous ISIN for the Company's shares: ISIN NO 0013251173
• New ISIN for the Company's shares: ISIN NO 0013711713 
• Date of ISIN change: 19 January 2026

***